{
  "trial_id": "NCT00655616",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Tayside (Scotland) known (a) to carry the Arg/Arg-16 genotype and (b) currently on inhaled steroids and (c) inhaled bronchodilators according to need will be telephoned or contacted through home visits to establish if they have had (a) any school absences from asthma or (b) out-of-hours visits to GP/hospital visits or admissions due to asthma over the previous 12 months.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Plan for each visit - First visit: (a) Documentation of patient details (b) Baseline spirometry; (c) Exhaled nitric oxide measurements (d) Respiratory quality-of-life (Juniper); (e) Saliva sample for eosinophilic cationic protein (f) discontinuation of current asthma medication for the period of the study; (g) randomization to receive either (a) Flixotide (fluticasone) as per current inhaled steroid dose (therapeutic ratio of 2:1 for beclomethasone / budesonide versus fluticasone) plus oral montelukast; or (b) Seretide (salmeterol plus equivalent dose of fluticasone) plus placebo for montelukast for a period of 1 year.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "2nd -5th visits, month 3, 6, 9: 3-monthly spirometry, exhaled nitric oxide, saliva for eosinophilic cationic protein, document school absences for asthma, hospital admissions/hospital or out-of-hours GP visits over the 3-month period.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Month 12: end of study - spirometry, exhaled nitric oxide, saliva for eosinophilic cationic protein, document school absences for asthma, hospital admissions/hospital or out-of-hours GP visits over final 3-month period, measure quality-of-life.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Physical monitoring of compliance will be performed by using inhalers provided with counters and tablet dispensers that allow counting of number used.",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "The presence of serious respiratory or multi-system disease (e.g. cystic fibrosis, cancer under current treatment)",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "39-year-old man with cough and shortness of breath that was not relieved by his inhaler. He had these symptoms for 5 days during the past 2 weeks. He doubled his oral corticosteroids in the past week.",
  "_meta": {
    "topic_id": "23",
    "trial_id": "NCT00655616",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}